These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 7625239

  • 1. [Study of the evolution of some monocytic parameters and neuroendocrine function tests in depressed patients].
    Cervera Enguix S, Rodríguez-Rosado A, Ramos Ruiz F, Sarrais Oteo F, Pla Vidal J, Rodríguez-Rosado R.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(2):67-73. PubMed ID: 7625239
    [Abstract] [Full Text] [Related]

  • 2. Neuroendocrine and immunological functions in depressed patients: a follow-up study.
    Cervera-Enguix S, Rodríguez-Rosado A.
    Eur Psychiatry; 1995; 10(1):49-55. PubMed ID: 19698315
    [Abstract] [Full Text] [Related]

  • 3. [Influence of depressive history on biological parameters in major depression].
    Van Wijnendaele R, Hubain P, Dramaix M, Mendlewicz J, Linkowski P.
    Encephale; 2002; 28(1):51-8. PubMed ID: 11963343
    [Abstract] [Full Text] [Related]

  • 4. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression.
    Wichniak A, Brunner H, Ising M, Pedrosa Gil F, Holsboer F, Friess E.
    Psychoneuroendocrinology; 2004 Oct; 29(9):1101-8. PubMed ID: 15219633
    [Abstract] [Full Text] [Related]

  • 5. [Usefulness of neuroendocrine function tests in the differential diagnosis of depression].
    Cervera S.
    Rev Esp Fisiol; 1989 Oct; 45 Suppl():279-87. PubMed ID: 2518335
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
    Owashi T, Otsubo T, Oshima A, Nakagome K, Higuchi T, Kamijima K.
    Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
    [Abstract] [Full Text] [Related]

  • 7. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression.
    Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, Müller-Oerlinghausen B, Bauer M.
    Depress Anxiety; 2003 Feb; 17(1):43-8. PubMed ID: 12577277
    [Abstract] [Full Text] [Related]

  • 8. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S, Ferreri M, Cabanac F, Bitton M.
    Encephale; 2003 Feb; 29(5):438-44. PubMed ID: 14615693
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder.
    Isogawa K, Nagayama H, Tsutsumi T, Kiyota A, Akiyoshi J, Hieda K.
    J Psychiatr Res; 2005 Sep; 39(5):467-73. PubMed ID: 15992555
    [Abstract] [Full Text] [Related]

  • 10. Neuroendocrine abnormalities in affective disorders.
    Extein I, Pottash AL, Gold MS.
    Encephale; 1982 Sep; 8(2):203-11. PubMed ID: 6809445
    [Abstract] [Full Text] [Related]

  • 11. [Monocytic dysfunction by opioid peptides in patients with major depression].
    Castilla A, Subirà ML, Civeira MP, Cuende JI, Prieto J.
    Med Clin (Barc); 1992 Sep 12; 99(7):241-3. PubMed ID: 1405803
    [Abstract] [Full Text] [Related]

  • 12. Opioid peptides and immunodysfunction in patients with major depression and anxiety disorders.
    Castilla-Cortázar I, Castilla A, Gurpegui M.
    J Physiol Biochem; 1998 Dec 12; 54(4):203-15. PubMed ID: 10225412
    [Abstract] [Full Text] [Related]

  • 13. The application of serial neuroendocrine challenge studies in the management of depressive disorder.
    Targum SD.
    Biol Psychiatry; 1983 Jan 12; 18(1):3-19. PubMed ID: 6403062
    [Abstract] [Full Text] [Related]

  • 14. [Depression of the mononuclear phagocyte system caused by high doses of narcotics].
    Carrera J, Catalá JC, Monedero P, Carrascosa F, Arroyo JL, Subirá ML.
    Rev Med Univ Navarra; 1992 Jan 12; 37(3):119-25. PubMed ID: 1336212
    [Abstract] [Full Text] [Related]

  • 15. Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation.
    Reppermund S, Zihl J, Lucae S, Horstmann S, Kloiber S, Holsboer F, Ising M.
    Biol Psychiatry; 2007 Sep 01; 62(5):400-6. PubMed ID: 17188252
    [Abstract] [Full Text] [Related]

  • 16. Changes in hypothalamic-pituitary-adrenal axis measures after vagus nerve stimulation therapy in chronic depression.
    O'Keane V, Dinan TG, Scott L, Corcoran C.
    Biol Psychiatry; 2005 Dec 15; 58(12):963-8. PubMed ID: 16005439
    [Abstract] [Full Text] [Related]

  • 17. Neuroendocrine dysfunction and response to tricyclic antidepressants.
    Kirstein L.
    J Clin Psychiatry; 1984 Sep 15; 45(9):385-6. PubMed ID: 6432772
    [Abstract] [Full Text] [Related]

  • 18. Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression.
    Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Weissenburger JE, Fulton CL, Fairchild CJ, Roffwarg HP.
    Biol Psychiatry; 1997 May 01; 41(9):915-28. PubMed ID: 9110097
    [Abstract] [Full Text] [Related]

  • 19. Neuroendocrine stimulatory tests of hypothalamus-pituitary-adrenal axis in psoriasis and correlative implications with psychopathological and immune parameters.
    Karanikas E, Harsoulis F, Giouzepas I, Griveas I, Chrisomallis F.
    J Dermatol; 2009 Jan 01; 36(1):35-44. PubMed ID: 19207435
    [Abstract] [Full Text] [Related]

  • 20. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I.
    Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ.
    Biol Psychiatry; 1995 Dec 15; 38(12):797-802. PubMed ID: 8750037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.